Thrombotic Microangiopathies Flashcards

1
Q

How can you clinically differentiate TTP from HUS?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

True or false: The treatment of choice for TTP is plasma exchange.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

True or false: Platelet transfusion is the treatment of choice for TTP.

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What type of anaemia is the hallmark in TMA?

A

MAHA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

True or false: Iron deficiency anaemia is the hallmark in TMA.

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the most correct statement regarding TTP and HUS?

A

HUS is a more common cause of ARF than TTP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the classic pentad features of TTP?

A
  • Microangiopathic haemolytic anaemia
  • Thrombocytopenia
  • Renal insufficiency or abnormalities
  • Neurologic abnormalities
  • Fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What accounts for >99% of adolescent and adult cases of TTP?

A

Acquired TTP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What autoimmune condition is associated with TTP?

A

Anti-ADAMTS-13 antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What does decreased ADAMTS13 activity lead to?

A

Accumulation of UL vWF multimers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

TTP is a _______ diagnosis.

A

clinicopathological

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is considered pathologic in terms of schistocytes on a blood film?

A

More than two schistocytes per high-power field or > 1.0% schistocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the cornerstone of current management of TTP?

A

Therapeutic Plasma Exchange (TPE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the recommended dosage of prednisone for TTP treatment?

A

1 mg/kg/day orally followed by a rapid taper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Without therapy, the mortality rate of TTP exceeds _____%.

A

90

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What should be assayed before beginning therapy for TTP?

A

ADAMTS13 activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What laboratory features are indicative of TTP?

A
  • Anaemia
  • Thrombocytopenia
  • Schistocytes
  • Elevated LDH
  • Unconjugated hyperbilirubinaemia
  • Reduced haptoglobin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the major component of the hemostatic system?

A
  • Vascular endothelium
  • Platelets
  • Coagulation and fibrinolytic systems
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the incidence of TTP in adults?

A

About 3 per 1,000,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TTP has a higher incidence in which gender?

A

Female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the primary cause of ADAMTS13 deficiency in acquired TTP?

A

Autoantibodies to ADAMTS13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the role of ADAMTS13?

A

Cleaves vWF

23
Q

What is a common feature of obstetric TTP?

A

Occurs during the second half of pregnancy

24
Q

True or false: HIV infection alters the prognosis of TTP.

25
Q

What characterizes HUS?

A

MAHA and thrombocytopenia

26
Q

What is the major clinical manifestation of HUS?

A

Renal disease

27
Q

What is the most common cause of acute renal failure in children?

28
Q

What is the inheritance pattern of aHUS?

A

Autosomal dominant

29
Q

What is the typical treatment for STEC-HUS?

A

Supportive care

30
Q

What is iculocytosis?

A

A clinical term related to the presence of schistiocytes in a peripheral blood smear

Schistiocytes are fragmented red blood cells often seen in conditions of hemolysis.

31
Q

What are elevated LDH levels indicative of?

A

Tissue damage, commonly associated with hemolytic conditions

LDH (lactate dehydrogenase) is an enzyme released during tissue injury.

32
Q

What clinical findings are associated with hemolytic uremic syndrome (HUS)?

A

Triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage

33
Q

What is the primary treatment for STEC-HUS?

A

Supportive care

Volume expansion within the first 4 days is crucial.

34
Q

What should be avoided in the management of STEC-HUS?

A

Antimotility agents

These can worsen the condition.

35
Q

True or False: Antibiotics are routinely recommended for STEC-HUS.

A

False

Use is controversial and only indicated for suspected sepsis or S. dysenteriae infection.

36
Q

What characterizes thrombotic microangiopathies (TMAs)?

A

MAHA, thrombocytopenia, and microthrombi leading to ischemic tissue injury

37
Q

What is the hallmark of thrombotic microangiopathy?

A

Microangiopathic hemolytic anemia (MAHA)

38
Q

What is the typical prognosis for patients with STEC-HUS?

A

Generally favorable, but chronic renal insufficiency may develop over time

39
Q

What is the incidence of atypical HUS (aHUS) in the USA?

A

Estimated at 2 per million

40
Q

What is a common cause of typical HUS?

A

Shiga toxin-producing E. coli (STEC)

Responsible for 90% of childhood HUS cases.

41
Q

Fill in the blank: The most common serotype associated with STEC-HUS is _______.

A

E. coli O157:H7

42
Q

What are some potential triggers for atypical HUS?

A

Varicella, H1N1 influenza

43
Q

What is the primary clinical feature of hemolytic uremic syndrome?

A

Thrombotic microangiopathy (TMA)

44
Q

What are the main pathological lesions in HUS?

A

Thickening of arterioles, endothelial swelling, and detachment

45
Q

What is the typical age of onset for pediatric TTP?

A

Typically occurs during infancy or early childhood (<10 years)

46
Q

What is the role of Eculizumab in aHUS management?

A

Inhibits C5 activation and prevents TMA process

47
Q

What percentage of children with STEC-HUS require dialysis during the acute phase?

48
Q

What are alloantibodies?

A

Antibodies produced against transfused blood cells from another individual

49
Q

What conditions can cause alloantibodies?

A
  • Hemolytic disease of the newborn
  • Incompatible blood transfusion
50
Q

What distinguishes autoantibodies from alloantibodies?

A

Autoantibodies are directed against one’s own RBCs

51
Q

What are some common causes of autoimmune hemolytic anemia?

A
  • Systemic lupus erythematosus (SLE)
  • Other autoimmune diseases
52
Q

What is the usual outcome for D(+) HUS?

A

Self-limiting, but residual renal dysfunction is common

53
Q

What is the significance of DAT in hemolytic anemia?

A

Direct Antiglobulin Test (DAT) indicates the presence of autoantibodies